Inactive Instrument

Enzymotec Ltd. Stock

Equities

ENZY

IL0011296188

Commodity Chemicals

Dynamic Chart
Aker Biomarine Antarctic AS acquired Krill Oil Business of Enzymotec Ltd. for $26.4 million. CI
Enzymotec Ltd.(NasdaqGS:ENZY) dropped from NASDAQ Composite Index CI
Frutarom Ltd. completed the acquisition of the remaining 81.3% stake in Enzymotec Ltd. from Paulson & Co. Inc. and others for approximately $230 million. CI
Enzymotec Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017 CI
Transcript : Enzymotec Ltd., Frutarom Industries Ltd. - M&A Call
Enzymotec Ltd. Announces Signed A Definitive Agreement with Frutarom Industries Ltd CI
Enzymotec Ltd.(NasdaqGS:ENZY) dropped from S&P Global BMI Index CI
Enzymotec Ltd. acquired five nutritional supplements from Union Springs Healthcare, LLC for $27.9 million. CI
Frutarom Ltd. acquired an additional 9.2% stake in Enzymotec Ltd. from Paulson & Co. Inc. for $24.2 million. CI
Frutarom Industries Ltd. made an offer to acquire the remaining 81.3% stake in Enzymotec Ltd. from Paulson & Co. Inc. and others for approximately $220 million. CI
Enzymotec Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017 CI
Enzymotec Ltd. Appoints Dror Israel as Vice President and Chief Financial Officer, Effective August 7, 2017 CI
Oren Bryan to Step Down as Vice President and Chief Financial Officer of Enzymotec Ltd CI
Enzymotec Ltd. Launches Krill Oil Product - K•REAL® Gold CI
Enzymotec Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017 CI
More news
Managers TitleAgeSince
Chief Operating Officer - 16-02-29
Sales & Marketing - 17-07-31
Human Resources Officer 59 14-08-28
Members of the board TitleAgeSince
Director/Board Member 68 13-08-31
More insiders
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
More about the company